Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xoft Axxent IOBT for Newly Diagnosed Glioblastoma
NCT07141732Phase 1Recruiting
- Sponsor
- European Medical Center
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by European Medical Center. Primary endpoint: Overall Survival at 36 months. Started Sep 2025; status: recruiting.
Beyond the preview
Go deeper on NCT07141732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07141732.